Report Id: SNS/HC/2649 | July 2022 | Region: Global | 129 Pages
Report Scope & Overview:
The Biopharmaceutical Excipients Market Size was valued at USD 2.37 billion in 2022, and expected to reach USD 3.96 billion by 2030, and grow at a CAGR of 6.6% over the forecast period 2023-2030.
In the upcoming years, it is anticipated that the market for biopharmaceutical excipients would expand significantly and is already witnessing a profitable rise. The macromolecules or biological components that are utilised to create genetically modified goods like blood products and other pharmaceuticals are known as biopharmaceutical products. In order to provide the necessary formulation with a longer shelf life for the product, biopharmaceutical excipients, which are inactive compounds employed as carriers, are coupled with the active pharmaceutical ingredients. Because biopharmaceutical molecules are prone to instability, the formulation's stability must be improved by the careful use of a combination of excipients.
These compounds have the ability to change taste, colour, elegance, binding capacity, and release rate of the active medicinal ingredient depending on the situation. Excipients and the active medicinal ingredients are needed in every biopharmaceutical composition. Excipients are primarily employed as binding agents, carriers, diluent excipients, co-processed excipients, emulsifier agents, and other stabilizing agents.
Significantly increasing need for big molecule development
Rapid expansion of the legal environment for the creation of biosimilars
The lack of common treatments will slow the market's rate of expansion.
Manufacturing of biopharmaceuticals is increasingly concentrated in developing nations.
Lack of awareness
IMPACT OF COVID-19
The need for macromolecules for therapy increased as a result of an infectious illness outbreak that had serious respiratory complications. In order to meet the growing demand for these macromolecules, biopharmaceutical excipients must improve stability and shelf life, which is expected to spur market expansion in the near future. The epidemic has prompted major firms to spend money on genetically altered molecules for better treating Covid-19 sufferers, which is anticipated to increase the use of pharmaceutical excipients in the near future.
The regulatory structure has additionally benefited the researchers with tax exemptions, which will enable the main leaders to generate the most income possible in the upcoming years. The pharmaceutical and biotechnology industries are currently going through a crisis. The market would, nevertheless, benefit from a higher number of market shares in the coming years due to the spike in demand for the development of medications with a longer shelf life.
By Product Type
The market was dominated by excipients with a carbohydrate base, and this trend is anticipated to persist during the projected period. The lion's share of the segment can be principally blamed for the extensive usage of starch, sucrose, and dextrose in different medication formulations. The segment's growth is also being aided by the growing use of carbohydrates as bulking agents to aid in the lyophilization of biomolecules like proteins.
Because starch is widely used in medication development, the starch category is anticipated to experience the fastest CAGR growth. It can function effectively as a binder, diluent, and disintegrant for a variety of over-the-counter drugs, biopharmaceuticals, and dietary supplements. Starch is used more frequently because of its benefits such cost effectiveness, inertness, and great availability.
Market expansion in the polyols area is predicted to be profitable. The increase in protein therapies is responsible for the segment's growth. Protein formulations contain polyols to improve stability and tonicity. Additionally, it has been demonstrated to have higher thermodynamic stability, which is crucial for protein-based formulations.
Some of the major key players are as follows: Associated British Foods, BASF SE, Colorcon, Clariant, DFE Pharma, Evonik Industries AG, IMCD, Sigachi Industries Pvt. Ltd., Merck KGaA, RETTENMAIER & SOHNE GmbH + Co KG, Roquette Freres, Signet Chemical Corporation Pvt, Ltd.
By Product type
Solubilizers & Surfactants/Emulsifiers
The greatest market share was held by North America, whose expansion can be ascribed to a number of elements including the existence of important players, an increase in drug research, and a sizable population base.
Collaborations between businesses in this region are being used to produce biopharmaceutical excipients.
The market is anticipated to expand at the quickest rate in Asia Pacific as a result of the existence of sizable CMOs engaged in drug development. India, China, and South Korea are among the nations in this region that are heavily involved in the development of biosimilars. The extensive development of biosimilars has occurred for a number of reasons, including affordability, a supportive regulatory environment, cost advantages, and the existence of a sizable population base. In order to assure drug stability, biopharmaceutical excipients are needed for the development of biosimilars.
Rest of Europe
Rest of Asia-Pacific
The Middle East & Africa
Rest of Middle East & Africa
Rest of Latin America
|Market Size in 2022||US$ 2.37 Billion|
|Market Size by 2030||US$ 3.96 Billion|
|CAGR||CAGR of 6.6% From 2023 to 2030|
|Report Scope & Coverage||Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook|
|Key Segments||• by Product type (Solubilizers & Surfactants/Emulsifiers (Triglycerides, Esters), Polyols (Mannitol, Sorbitol), Carbohydrates (Sucrose, Dextrose, Starch), Specialty Excipients)|
|Regional Analysis/Coverage||North America (USA, Canada, Mexico), Europe
(Germany, UK, France, Italy, Spain, Netherlands,
Rest of Europe), Asia-Pacific (Japan, South Korea,
China, India, Australia, Rest of Asia-Pacific), The
Middle East & Africa (Israel, UAE, South Africa,
Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America)
|Company Profiles||Associated British Foods, BASF SE, Colorcon, Clariant, DFE Pharma, Evonik Industries AG, IMCD, Sigachi Industries Pvt. Ltd., Merck KGaA, RETTENMAIER & SOHNE GmbH + Co KG, Roquette Freres, Signet Chemical Corporation Pvt, Ltd.|
|Key Drivers||• Significantly increasing need for big molecule development
• Rapid expansion of the legal environment for the creation of biosimilars
|RESTRAINTS||• The lack of common treatments will slow the market's rate of expansion.|
Frequently Asked Questions (FAQ) :
Ans Biopharmaceutical Excipients Market Size was valued at USD 2.23 billion in 2021, and expected to reach USD 3.50 billion by 2028, and grow at a CAGR of 6.6% over the forecast period 2022-2028.
Ans. Significantly increasing need for big molecule development, and Rapid expansion of the legal environment for the creation of biosimilars are the key drivers of the Biopharmaceutical Excipients market
Ans. The greatest market share was held by North America.
Ans. Associated British Foods, BASF SE, Colorcon, Clariant, DFE Pharma, Evonik Industries AG, IMCD, Sigachi Industries Pvt. Ltd are the key players of Biopharmaceutical Excipients market
Ans. Lack of awareness is the challenges faced by Biopharmaceutical Excipients market.
Table of Contents
1.1 Market Definition
1.3 Research Assumptions
2. Research Methodology
3. Market Dynamics
4. Impact Analysis
4.1 COVID-19 Impact Analysis
4.2 Impact of Ukraine- Russia war
4.3 Impact of ongoing Recession
4.3.2 Impact on major economies
188.8.131.52 United Kingdom
184.108.40.206 South Korea
220.127.116.11 Rest of the World
5. Value Chain Analysis
6. Porter’s 5 forces model
7. PEST Analysis
8. Biopharmaceutical Excipients Market Segmentation, By Product type
8.1 Solubilizers & Surfactants/Emulsifiers
8.4 Specialty Excipients
9. Regional Analysis
9.2 North America
9.3.6 The Netherlands
9.3.7 Rest of Europe
9.4.2 South Korea
9.4.6 Rest of Asia-Pacific
9.5 The Middle East & Africa
9.5.3 South Africa
9.6 Latin America
9.6.3 Rest of Latin America
10.1 Associated British Foods
10.1.2 Products/ Services Offered
10.1.3 SWOT Analysis
10.1.4 The SNS view
10.2 BASF SE
10.5 DFE Pharma
10.6 Evonik Industries AG
10.8 Sigachi Industries Pvt. Ltd.
10.9 Merck KGaA
10.10 RETTENMAIER & SOHNE GmbH + Co KG
11.1 Competitive Benchmark
11.2 Market Share analysis
11.3 Recent Developments
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of the good and accurate research report and selecting the best methodology to complete the research is the toughest part. Since the research reports, we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brainstorming sessions to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploaded on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.